326 related articles for article (PubMed ID: 23083854)
21. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
22. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
23. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes.
Sourvinos G; Kazanis I; Delakas D; Cranidis A; Spandidos DA
J Urol; 2001 Jan; 165(1):249-52. PubMed ID: 11125419
[TBL] [Abstract][Full Text] [Related]
24. [Detection of bladder cancer in voided urine samples].
Thomas A; Renard I; Waltregny D
Rev Med Liege; 2009; 64 Spec No():9-14. PubMed ID: 20085009
[TBL] [Abstract][Full Text] [Related]
25. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
[TBL] [Abstract][Full Text] [Related]
26. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
Szarvas T
Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
[TBL] [Abstract][Full Text] [Related]
27. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
28. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC
J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397
[TBL] [Abstract][Full Text] [Related]
29. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
Nakayama G; Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A
Anticancer Res; 2007; 27(3B):1459-63. PubMed ID: 17595762
[TBL] [Abstract][Full Text] [Related]
30. [Significance of a simple assay of urine telomerase activity for the detection of bladder cancer].
Iwabuchi I; Mori K; Yamamoto H; Hatakeyama S; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Suzuki T; Ohyama C
Hinyokika Kiyo; 2010 Oct; 56(10):551-7. PubMed ID: 21063158
[TBL] [Abstract][Full Text] [Related]
31. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
[TBL] [Abstract][Full Text] [Related]
32. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer.
Tölle A; Jung M; Rabenhorst S; Kilic E; Jung K; Weikert S
Oncol Rep; 2013 Oct; 30(4):1949-56. PubMed ID: 23877086
[TBL] [Abstract][Full Text] [Related]
33. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic alterations of adenomatous polyposis coli (APC), retinoic acid receptor beta (RARβ) and survivin genes in tumor tissues and voided urine of bladder cancer patients.
Berrada N; Amzazi S; Ameziane El Hassani R; Benbacer L; El Mzibri M; Khyatti M; Chafiki J; Abbar M; Al Bouzidi A; Ameur A; Attaleb M
Cell Mol Biol (Noisy-le-grand); 2012 Sep; Suppl.58():OL1744-51. PubMed ID: 22992440
[TBL] [Abstract][Full Text] [Related]
35. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.
Ellinger J; El Kassem N; Heukamp LC; Matthews S; Cubukluoz F; Kahl P; Perabo FG; Müller SC; von Ruecker A; Bastian PJ
J Urol; 2008 Jan; 179(1):346-52. PubMed ID: 18006010
[TBL] [Abstract][Full Text] [Related]
36. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
37. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
39. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
